Princeton Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

Princeton Capital Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,717	Closed	-$281K	–	113
2021 Q2	$281K	Buy	+1,717	New	+$264K	0.09%	94
2019 Q3	–	Sell	-330	Closed	-$36K	–	249
2019 Q2	$36K	Hold	330	–	–	0.02%	167
2019 Q1	$37K	Hold	330	–	–	0.02%	163
2018 Q4	$32K	Hold	330	–	–	0.02%	169
2018 Q3	$40K	Buy	330 +165	+100%	+$19.4K	0.02%	180
2018 Q2	$18K	Hold	165	–	–	0.01%	231
2018 Q1	$18K	Buy	+165	New	+$18.3K	0.01%	221

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Princeton Capital Management's IBB Position: Q3 2021 in Review

Princeton Capital Management sold out of iShares Biotechnology ETF (IBB) in Q3 2021, closing a stake of 1,717 shares — an estimated $281K sold.

Princeton Capital Management first reported a position in IBB in Q1 2018 and held it in 7 quarters. The position peaked at $281K in Q2 2021. 855 funds tracked by Wall St. Rank hold IBB as of Q3 2021.

Princeton Capital Management reported no remaining iShares Biotechnology ETF position as of Q3 2021 after selling out during the quarter.
Princeton Capital Management sold 1,717 iShares Biotechnology ETF shares in Q3 2021, an estimated $281K.
Princeton Capital Management first reported a position in iShares Biotechnology ETF in Q1 2018 and held it in 7 quarters.
Princeton Capital Management's iShares Biotechnology ETF position peaked at $281K in Q2 2021.
855 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2021.

Based on Princeton Capital Management's 13F filing for Q3 2021, filed 10 Nov 2021.